Co-administration of Cabergoline and Gliclazide Improve Glycemic Parameters and Lipid Profile in T2DM Patients

Last updated: August 23, 2018
Sponsor: Sherief Abd-Elsalam
Overall Status: Active - Recruiting

Phase

3

Condition

Diabetic Kidney Disease

Diabetic Foot Ulcers

Diabetic Gastroparesis

Treatment

N/A

Clinical Study ID

NCT03313661
Diabetes Mellitus
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

Evaluation of the glycemic efficacy of cabergoline on diabetic patients

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Diabetic patients.

Exclusion

Exclusion Criteria:

  • Other drugs administration

Study Design

Total Participants: 60
Study Start date:
October 14, 2017
Estimated Completion Date:
December 31, 2020

Study Description

Type 2 diabetes mellitus (DM) is a progressive metabolic disorder that is associated with basal hyperinsulinemia, insulin resistance and impaired insulin release. Glycemic control is a fundamental part of the management of type 2 DM and difficult to achieve. Different antidiabetic agents can handle diabetic metabolic abnormalities. The development of antidiabetic agentswith novel mechanisms of action is highly desirable. Cabergoline, a long acting D2 agonist, is expected to play a role in the glycemic control.

Connect with a study center

  • Sherief Abd-Elsalam

    Cairo,
    Egypt

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.